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Summary 
 Tuberculosis (TB) is a communicable disease in humans caused most commonly by 
Mycobacterium tuberculosis and less commonly by other bacterial species in the Mycobacterium 
tuberculosis complex (Africanum, bovis, microti, etc.). A strictly followed drug regimen administered 
by directly observed therapy (DOT) is the standard of treating TB, due to the severity of 
consequences of treatment non-compliance (e.g. acquired drug resistance). Prevention and 
management of TB is best done by targeted testing of at-risk populations, management and 
treatment of both latent and active TB cases, contact investigations of cases, and properly applied 
infection control methods. 
The Kansas Tuberculosis Control Program (founded 1901) currently supports local public 
health agencies, physicians, and health care facilities responsible for TB control and management, 
and provides medications for nearly 90% of Kansas TB cases. However, the program does not 
provide a structured guide for TB management and control, and health care workers rely on 
outside source manuals for referral during TB care. In the event of a TB outbreak, it is critical that 
clear and concise health communication is exchanged between the health care workers who 
administer DOT and the TB patients. Therefore, as the fieldwork’s primary objective, a TB protocol 
manual was developed, using adapted literature review, to cater to the Saline County Health 
Department’s Communicable Disease/TB Program and other local Kansan health departments if 
they choose to adopt the manual. 
 Comprised in this report are the learning objectives and competencies required for the 
culminating experience, all relevant data visualizations and analyses, and the document produced 
(SCHD Guidelines for the Prevention, Diagnosis, and Treatment of Tuberculosis 2017), completed 
in partial fulfillment of the requirements for the Master of Public Health degree from Kansas State 
University. The field experience was conducted at the Saline County Health Department, a county-
level health agency serving the residents of Salina and several neighboring communities. 
 
Subject Keywords: TB Mycobacterium Tuberculosis Prevention Diagnosis Treatment  
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Chapter 1 - Field Experience: Saline County Health Department 
 1.1) Scope of Work 
Many opportunities were made available to me during my fieldwork experience at the Saline 
County Health Department (SCHD), a county-level health agency that serves the city of Salina 
(population ~55,000) and its neighboring communities. Jason Tiller, the director of the SCHD, 
served as my mentor and helped to provide ample learning opportunities that involved both hands-
on and observational activities throughout the health department.  
The SCHD is comprised of seven different departments that work both independently and 
collaboratively to increase the health of Saline County’s citizens: 1) Women Infants & Children 
(WIC), 2) Maternal and Child Health (MCH), 3) Home Health, 4) Child Care Licensing, 5) Health 
Education, 6) Nursing Clinic, and 7) Public Health Emergency Preparedness (PHEP). I was 
fortunate enough to either observe or gain direct experience with several of the departments’ daily 
functions. In addition, I increased my knowledge of diseases and gained experience with the 
disease reporting process through the use and observation of Epitrax, the electronic disease 
surveillance system for Kansas. 
After conversing with the communicable disease/TB program manager (Maria Shoultys, 
RN), about the potential helpfulness of a customized TB manual as part of a health department’s 
TB protocol for response and prevention, I decided to develop such a document as my capstone 
project. After graphically and statistically analyzing CDC WONDER (public data) as well as Kansas 
TB datasets, the manual was further developed to be customizable to the analysis-observed 
underserved subpopulations of Kansas. 
 
 
 
Figure 1.1 The Saline County Health Department Logo 
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Chapter 2 - Objectives, Activities, and Products 
 2.1) Learning Objectives (3): 
1) Broaden experiences in a local health department setting to become better acquainted with 
different aspects of public health. 
 
2) Learn how the different branches of a health department work together to improve the health of 
the community it serves. 
 
3) Broaden knowledge and experiences pertaining to infectious diseases/zoonoses. 
 
 2.2) Activities Performed: 
1) “Attend meetings/conferences that pertain to public health.” 
 Central Kansas Region for PHEP (Public Health Emergency Preparedness): A meeting 
between health department directors from central Kansan counties (Stafford, Barton, 
Pawnee, Rice, and Saline) to discuss current public health events, grant spending, and 
issues regarding emergency preparedness. 
 KAHLD (Kansas Association of Local Health Departments): A nonprofit conference, 
hosting mainly local health department directors, designed to strengthen public health in 
Kansas. Lectures about bioinformatics, public health modernization, and health 
communication using multiple platforms. 
 LiveWell Saline County: A meeting between 5 different local organization representatives 
to discuss Saline County wellness plans regarding healthy eating habits, LiveWell grant 
funding, and Food Systems Assessments.  
 Kansas Healthy Living: A meeting between about 15 representatives from different 
organizations in Salina, KS (e.g. the Salvation Army, Heartland Early Education, Saline 
Family Health Care, etc.) to discuss county health issues. 
 Becoming a Mom Series: An educational series of meetings presented by the Maternal 
and Child Health (MCH) department, for new mothers to promote health pregnancies. 
 
2) “Become familiar with all aspects of a local health department (Finance, WIC, MCH, Home 
Health, Child Care Licensing, Health Education, Nursing Care, and PHEP).” 
 Gained experience with Epitrax (KDHE’s Electronic Disease Surveillance System). 
 Researched current events (e.g. lead poisoning) that apply to Saline county as well as other 
relevant, common infectious diseases. 
 Observed procedures in the Communicable Disease department. 
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 D.O.T. treatment for extrapulmonary TB / LTBI cases 
 TB skin testing preparation and procedure 
 Participated in health education outreach with children attending HYPE (Helping Youth 
Pursue Excellence) to promote handwashing and other healthy behaviors. 
 
3) “Work on research project.” 
 Performed data analyses and statistical tests and produced graphic visualizations with 
public CDC WONDER TB data (years 1993-2015) and Kansas TB data (years 2012-2017) 
using R to better understand disease trends. 
 Developed a TB protocol manual that caters to the needs of SCHD’s Communicable 
Disease/Tuberculosis Program and customized the manual for health care workers to better 
serve the more critically-affected subpopulations of TB patients in Kansas. 
 
     
      Figure 2.1 Attending the KALHD Conference           Figure 2.2 Testing PPE (PHEP Meeting) 
 
 
  
  Figure 2.3 LiveWell Saline County Meeting 
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Figure 2.4 Preparation and delivery of healthy behavior education 
(promoting handwashing) to children attending HYPE in Salina, KS 
 2.3) Products Developed: 
After discovering the need for a TB protocol manual that can be utilized by the health care 
workers at the SCHD, I developed one such manual that is adapted to the needs of Saline County 
and possibly to other local health departments in Kansas. The focus of this manual was to be 
concise and understandable without compromising the quality of information. It is further explained 
in Chapter 3 and included in the Appendix. 
 
 
Figure 2.5 The SCHD Guidelines for the Prevention,  
Diagnosis, and Treatment of Tuberculosis (2017) 
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Chapter 3 - Capstone Project 
MPH Competencies (5): 
The 5 competencies that must be met via a culminating experience (integrating knowledge 
acquired in MPH coursework and applying theory and principles in situations that approximate an 
aspect of professional practice) are outlined below. 
1) Biostatistics 
Basic techniques of descriptive and inferential statistical methods such as sampling 
distributions for hypothesis testing are covered in MPH biostatistical coursework and first 
influenced my interest in data analysis. During my MPH training, I was exposed to statistical 
analysis programs (e.g. SAS) from various courses, and it opened my eyes to the endless 
applications that epidemiological data analysis could have for public health outcomes and decision 
making. During my fieldwork at the SCHD, I performed statistical analyses on public TB data from 
CDC WONDER and visualized TB trends with descriptive graphs in R using package ‘ggplot2’ to 
assist with the customizable production of my capstone project. 
2) Environmental Health Sciences 
Environmental impacts as it relates to public health outcomes is very important, especially 
in respect to TB control and management. During the fieldwork, I attended a Central Kansas PHEP 
meeting in Lyons, KS, where I met with the health directors from 5 different counties. Some of the 
issues that were addressed included the necessity to purchase certain PPE equipment and what to 
do with expired equipment that could no longer serve its purpose. 
During the researching of TB protocols, I found that personal protective equipment (PPE), 
medical waste, and airborne infection isolation (AII) were critically underappreciated, yet important 
aspects of TB management and control. By researching the various, unique requirements that 
Kansas had for its adult care homes, correctional facilities, and hospital care settings, I gained a 
deeper appreciation for the impact that disease control can have upon the environment. 
3) Epidemiology 
Epidemiologic coursework taken for the MPH degree (e.g. Epidemiology, Virology, 
Toxicology, Immunology, etc.) all revolved around how to recognize and understand how disease 
affects both individuals and populations alongside the methods for management and control of 
8 
 
these diseases. While producing the TB protocol manual, I found that much of the CDC-based TB 
control methods were created with respect to the epidemiological triad (Host, Agent, & 
Environment). By using the principles and theory gained from coursework, I developed my 
capstone project to address all aspects of management and control for TB’s host (humans or 
animals), agent (M. tuberculosis and its pathogenic mechanisms), and Environment (settings for 
optimal TB control). In addition, when learning about various infectious disease outbreaks by 
utilizing the electronic disease surveillance system for Kansas (Epitrax), I utilized epidemiological 
theory to view the outbreaks from unique perspectives.  
4) Health Services Administration 
Health service administration is very important to public health outcomes, as it brings about 
policies that govern how certain situations are handled. During my fieldwork, I attended many 
meetings and found that the primary focus of many of these meetings entailed how grants could 
better be obtained or allocated. For example, in Kansas, the allocation of governmental funds for 
local health departments are passed down via many upper-level bodies of government and 
ordinances such as the state health department and county commissioners. I learned about the 
importance of good health communication strategies as it relates to Community Health 
Assessments and need-based reports for grants to support effective health outcomes. 
In addition, I researched the significant costs of TB treatments and realized that policy 
regulation and prevention is important for mitigating expenditures. In the TB protocol manual, a 
section titled “Managing Non-Adherence” was included, which entails the state ordinances (Kansas 
State Statutes) that dictate the rules that must be followed during investigation or control of a TB 
case/outbreak. 
5) Social and Behavioral Sciences 
For TB contact investigations and various cultural sensitivity issues, I found that proper 
application and understanding of social and behavioral sciences is critical in TB management. After 
realizing that TB is a highly stigmatizing disease in many cultures, I decided to promote a fostering 
of good cultural issue awareness for health care workers utilizing the SCHD TB manual by 
including a section titled “Promoting Cultural Sensitivity”. The contact investigation section of the 
manual also addresses social and behavioral issues by promoting good rapport with interviewed 
TB patients to increase compliance and mitigate future outbreaks. 
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 “Developing a Tuberculosis  
Protocol Manual for the SCHD” 
 
Part 1: Introduction 
3.1.1) Needs of the SCHD: 
The inspiration for this capstone project arose when SCHD’s needs were discussed 
between the Communicable Disease / TB Program Manager (Maria Shoultys, RN) and myself. The 
Kansas Department of Health and Environment (KDHE) currently has a tuberculosis control 
program and offers helpful links on their webpage to obtain information, but does not offer 
a TB protocol manual that local health departments can utilize for TB management and 
control. Maria stated that the policies and procedures that she implements for TB case 
managements are based primarily off CDC recommendations and occasionally, TB manuals from 
other states (Nebraska & Maryland) are utilized. 
 
3.1.2) Capstone Project Objective: 
After careful consideration of the requirements needed for a comprehensive and accurate 
TB protocol manual, the objective of the capstone project was formulated: Create a 
comprehensive and accurate TB protocol manual that caters to health care workers treating 
TB in Kansas as well as any underserved Kansan subpopulations. 
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Part 2: Methods 
3.2.1) Qualitative Research: 
To begin the process of developing a customized TB protocol manual for local health 
departments in Kansas, qualitative information regarding the pathological agent, current TB 
protocol manual information, economic impacts, and CDC guidelines were reviewed. 
 
Tuberculosis Literature Review 
Background: 
 Tuberculosis (TB) is a communicable disease in humans caused most commonly by 
Mycobacterium tuberculosis and less commonly by other bacterial species in the Mycobacterium 
tuberculosis complex (Africanum, bovis, microti, etc).(30) The WHO estimates that yearly, about 9 
million people get sick with TB and about 2 million lives are claimed by this devastating disease.(4) 
 Before the discovery of the microbial causes of TB in 1882 by German microbiologist, 
Robert Koch, a TB epidemic plagued most parts of the world and killed 1 out of 7 people living in 
the United States and Europe. After Koch’s discovery, vaccines and drug treatments were 
developed to address the TB epidemic and although the World Health Organization (WHO) 
declared TB as a global emergency in 1993, cases have since decreased through exercise of 
proper disease prevention, management, and control. 
 
Transmission: 
Airborne (droplet nuclei) particles expelled (via coughing, sneezing, speaking, or singing) by 
a person with infectious, or active TB is the primary mode of transmission of TB. The particles are 
1-5 microns in diameter and depending on the environment, may remain suspended in the air for 
hours. The probability of TB transmission directly increases with an increase in the following 
factors: 1) susceptibility of the exposed individual, 2) infectiousness of the person with TB disease, 
3) environmental factors that affect the concentration of M. tuberculosis organisms, and 4) the level 
of exposure (proximity, frequency, & duration) to the infected individual.(30) 
Stopping transmission of TB is best done by promptly identifying and isolating patients with 
infectious TB and starting appropriate treatment. The level of infectiousness will decrease once the 
prescribed regimen is adhered to. This is most commonly done via Directly Observed Therapy 
(DOT), where a health care worker physically observes a TB patient ingest his or her medication. 
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Pathogenesis: 
When a person inhales air containing the droplet nuclei containing tubercle bacilli, the 
alveolar macrophages within the lung’s alveoli ingest and inhibit most tubercle bacilli, but some 
bacilli are able to replicate in the host macrophage. After replicating intracellularly, the bacilli are 
released when the macrophages die and can travel via lymphatic channels to regional lymph 
nodes or via the bloodstream to other locations such as the kidneys, brain, and bone, although in 
most cases, the infection remains localized to the apices of the lungs.(30) 
When a person is infected with TB bacilli but is asymptomatic, isn’t contagious, and returns 
a positive reaction on the tuberculin skin test (TST), they have latent TB infection (LTBI). It is 
estimated that without treatment, about 5 to 10% of those with LTBI eventually develop active TB 
disease, which is characterized by morbidity, contagiousness, and indicative chest x-ray (CXR) 
findings or positive TB diagnostic tests. Immunocompromised individuals (e.g. HIV/AIDS patients) 
have a considerably higher risk of developing active TB disease.(29) 
Multi-drug resistant TB, or MDR-TB, is caused by an organism that is resistant to at least 
isoniazid and rifampin, the two most potent TB drugs. These drugs are used to treat all persons 
with TB disease. Extensively drug resistant TB, or XDR-TB, is a rare type of MDR-TB that is 
resistant to isoniazid and rifampin, along with any fluoroquinolone and at least one of three 
injectable second-line drugs such as amikacin, kanamycin, or capreomycin. Patients infected with 
XDR-TB strains have a high chance of developing TB disease and have high mortality rates.(16)  
 
Review of TB Protocol Manuals from Other States 
 To gain a general idea of how a TB protocol manual is structured, different manuals were 
accessed and reviewed. Among them are protocols from Nebraska Department of Health and 
Human Services, Maryland Department of Health and Hygiene, Washington State Department of 
Health, and the County of Los Angeles Tuberculosis Control Program. Among those manuals, I 
decided to compare the manuals that SCHD’s Communicable Disease / TB Program manager 
referred to most frequently: Nebraska and Maryland. (See Table 1.) 
 Upon comparing Nebraska and Maryland’s TB protocol manuals, the decision to include 
detailed CDC-based instructions and graphics for the Tuberculin Skin Test procedure was made. 
Also, the logical order for the different parts of the CDC manual was decided: 1) Introduction to TB, 
2) Latent TB Infection Management, 3) Active TB Management, 4) Adherence Promoting 
Strategies, 5) Contact Investigations / Infection Control, and 6) References and Appendices. 
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                     Nebraska TB Manual    Maryland TB Manual 
Figure 3.1 A comparison of TB protocol manuals from Nebraska and Maryland 
 
Table 1. Comparison of Pros & Cons for TB Manuals for Nebraska & Maryland 
Nebraska Maryland 
Pros: Cons: Pros: Cons: 
Logical order of 
presentation. 
No graphics, figures, 
tables, or cover page. 
Some graphics and 
includes cover page. 
No Tuberculin Skin Test 
instructions. 
Includes very detailed TB 
Skin Test instructions. 
Some aspects are not 
explained in enough detail 
(e.g. “Treatment of TB” 
section- had little to no 
explanation. 
Very thorough and 
includes a logical order 
of presentation that is 
easy to follow. 
Some of the guidelines are 
too study-focused instead of 
practice-focused. Not ideal 
for a health care worker to 
follow and implement. 
Brevity of Information 
where it is needed. 
Small font and no 
distinguishable spacing 
between the sections. 
Includes many 
customizable factors that 
relate to Maryland. 
No graphics to help in 
understanding certain 
procedures. 
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Economic Impacts of TB Treatment 
 The Communicable Disease / TB Program Manager created an opportunity for me to 
shadow her for a trip to observe the process of treating an elderly patient with extrapulmonary 
tuberculosis. This case was managed every day and the case manager travelled to the patient’s 
house daily to provide DOT. The total time expended from start to finish, including travel time (due 
to relative closeness of the patient to the health department), took about 30 minutes. 
 The cost of TB treatment is mostly borne by the public sector. According to a study done by 
the American Thoracic Society, the total monthly costs of treating a LTBI case were as follows: 9H: 
$26.37, 9H-DOT: $204.56, 3HP (with DOT): $167.82, and 4R: $53.07. Toxicity monitoring costs, 
which included lab monitoring, costs $158.36, and in the case of 7-day hospitalizations, the 
average cost estimate was $5,320.77, with the range being from $4250-$8000.(58) 
Active TB case management costs are even greater than LTBI treatment. For a 6-month 
treatment regimen, the total cost average was $12,511.71, and for a 9-month treatment regimen 
the total cost average was $13,246.57. In cases of drug resistance, care is even more complex 
and treatment is even more expensive. According to the CDC, the direct costs of treatment 
averaged $134,000 per MDR-TB patient and $430,000 per XDR-TB patient.(58) 
When observing the significant costs and time expenditures associated with TB treatment 
on the public sector, I realized that prevention is the best way to mitigate economic strains. 
Therefore, I decided to customize the manual to stress better methods for cost-control. 
 
CDC-Recommended Guidelines for TB Management/Control 
The Centers for Disease Control and Prevention (CDC) provides a rich array of information 
on its website pertaining to TB. The website’s main page provides information on TB management 
and control strategies as well as current publications. Most of the information used in creating the 
TB manual was either extracted directly from the CDC or otherwise, fact-checked based on CDC 
protocols. The main page pertaining to TB can be accessed at https://www.cdc.gov/tb. 
Upon review of the CDC website, a relatively new practice called “Electronic Directly 
Observed Therapy (e-DOT)” was encountered. This practice allows for the remote administration of 
DOT via use of electronic video-sharing devices. After observing the economic health care strains 
of TB treatment and for the purposes of keeping the product relevant for future use, the e-DOT 
program implementation instructions were incorporated into the manual. 
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3.2.2) Research Question: 
Upon literature review of TB, comparing the current TB protocol manuals, witnessing and 
studying the economic impacts of TB treatment, and extracting information from the CDC, one 
question remained: What are the specific needs of Saline County or Kansas local health 
departments as it relates to TB management and control? 
 
 
3.2.3) Quantitative Research: 
To answer the research question, I decided to observe data pertaining to TB in Kansas as 
well as public CDC TB data. Additionally, to better implement customized strategies (e.g. e-DOT, 
Google Translate), a survey was conducted among health care workers at the SCHD. 
 
Data Visualization (KS Active TB Case Data 2012-2017) 
From SCHD’s Communicable Disease / TB Manager, I obtained case files for all Kansan 
active TB cases from 2012- 2017. Detailed on those case files were patients’ demographic 
information and various patient risk factors. Anonymity of cases was strictly respected. 
Initially, the data was organized and manipulated to see if there was an observed trend that 
I could find via predictive modelling: risk factors causing resistance status (linear/polynomial 
regression), county class influencing percent chance of risk factors (logistic regression), and risk 
factors influencing count data (Poisson regression). However, due to an insufficient sample size, 
there was not a significantly producible model. Therefore, I decided to descriptively visualize the 
data with using package ‘ggplot2’ in R. 
After visually observing TB data from Kansas, I observed the following points for future 
analysis: 1) Kansas has a high amount of foreign-born active TB cases, and 2) drug resistance (to 
at least one first-line TB drug) among foreign-born cases was more frequently observed. 
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Demographic Visualization: 
 Upon visualizing the 167 Kansan active TB case files from 2012-2017, I obtained 
summaries of demographic information that allowed me to visualize exactly which populations were 
being most heavily afflicted. Descriptions of the observational summaries with their associated 
demographic variables are outlined in Table 2. 
 The observations of most significance involved ethnicity and country of birth of the cases. 
Kansan TB cases were predominantly born in the USA and countries closely following were 
Mexico, and India. However, ethnicity-wise, there was a predominance in the Asian community. 
This is further seen by looking at the numerous amounts of Asian countries of origin that contribute 
to the TB burden in Kansas. 
 
TABLE 2. Demographic Visualizations (Key for Figures 3.2 (a-j)) 
FIGURE 3.2: RANGE OF VALUES: OBSERVATIONS: 
(a) YEAR 2012 – 2017 (NOTE: 2017 is 
for a half-year) 
There was an observed spike in active TB cases in Kansas in 2013, but case 
counts have diminished in subsequent years. 
(b) AGE 1 – 92 The age range of active TB in Kansas appears to be fairly uniformly 
distributed. Mean and median age are around 48 with a standard deviation of 
about 10 years. 
(c) ETHNICITY Asian, Black, Hispanic, Native 
American, White 
Kansas active TB cases are most likely to be associated with Asian ethnicity. 
The next most common is White, closely followed by Hispanic and Black. 
(d) GENDER Female, Male Roughly 2 in 3 cases of active TB in Kansas are male. 
(e) ETHNICITY 
BY GENDER 
Female, Male // Asian, Black, 
Hispanic, Native American, 
White 
When looking at the ethnicity breakdown by gender, it is observed to be 
generally uniform. Proportionally, White and Black males have a slightly 
greater proportion of incidences than their female counterparts. 
(f) COUNTRY OF 
BIRTH 
Afghanistan – Vietnam 
(Alphabetical) 
The country of birth of Kansas active TB cases is predominantly the USA. 
The next three most common countries of birth are Mexico, India, and 
Vietnam. 
(g) COUNTY OF 
INCIDENCE 
Atchison – Wyandotte 
(Alphabetical) 
Sedgwick, Johnson, and Wyandotte counties are observed to have a higher 
active TB case count than any other Kansan county and these three counties 
have the highest populations in the state. 
(h) COUNTY 
POPULATION 
DENSITY (CPD) 
CLASSIFICATION 
MAP – Counties Classified By 
Population Density (ppsm) 
Values: Frontier, Rural, 
Densely-Settled Rural, Semi-
Urban, Urban 
This is a breakdown of Kansan counties, categorized by their population 
densities (in persons per square mile). The 5 classifications are given values 
of 1-5, with 1 being Frontier (least dense), and 5 being Urban (most dense) 
and is used for viewing the graphs of parts (c) and (d).  
(i) CPD 
CLASSIFICATION 
BREAKDOWN 
Reference: Figure 3.2 (h) 
Values: 1=Frontier, 2=Rural, 
3=Densely-Settled Rural, 
4=Semi-Urban, 5=Urban 
We observe the significant majority of Kansan active TB cases to be from 
1=Urban counties, with the second-most to be from 3=Densely-Settled Rural 
counties, closely followed by 4=Semi-Urban counties. Frontier and Rural 
counties don’t have many incidences of active TB. 
(j) CPD CLASS 
BROKEN DOWN 
BY ETHNICITY 
Reference: Figures 3.2 (h, i) When breaking down each county population density classification by 
ethnicity, it is observed that in classification 5 (Urban counties), there is a 
very high level of Asian TB cases. 
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(a) YEAR (NOTE: 2017 is half-year) 
Figure 3.2 (a) Visualizing Demographics by (a) Year of Incidence 
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(b) AGE 
Figure 3.2 (b) Visualizing Demographics by (b) Age of Patient 
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                        (c) ETHNICITY        (d) GENDER   
 
(e) ETHNICITY BY GENDER 
Figure 3.2 (c, d, e) Visualizing Demographics by (c) Ethnicity, (d) Gender, and (e) Gender 
Broken Down by Ethnicity 
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(f) COUNTRY OF BIRTH 
Figure 3.2 (f) Visualizing Demographics by (f) Country of Birth 
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(g) COUNTY OF INCIDENCE  
Figure 3.2 (g) Visualizing Demographics by (g) County of Incidence 
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(h) COUNTY POPULATION DENSITY (CPD) CLASS 
 
                   (i) CPD CLASS         (j) ETHNICITY BY CPD CLASS 
Figure 3.2 (h, i, j) (h) Classifying Counties by Population Density (CPD) and Visualizing 
Demographics by (i) CPD Class and (j) CPD Class broken down by Ethnicity 
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TB Risk Factor Visualization: 
 After obtaining the demographic information for the cases, the cases were also stratified 
further by known TB risk factors and observed for significant trends, as outlined in Table 3. 
Certain risk factors were more predominantly observed than others. The most important 
observation taken from this visualization was that roughly over 2 in 3 Active TB cases in Kansas 
were foreign-born (as compared to U.S.-born). Also, when plotting sensitivity status (resistance to 
at least one first-line anti-TB drug) against U.S. or foreign-born status and stratifying those data 
points by cases’ ethnicities, we can see that a predominant number of the resistant cases are 
foreign-born with Asian ethnic backgrounds. 
Upon seeing these risk factor visualizations in addition to the demographic visualizations, I 
decided to customize the manual to address the needs of foreign-born subpopulations in Kansas. 
 
TABLE 3. Risk Factor Visualizations (Key for Figures 3.3 (a-k)) 
FIGURE 3.3: RISK FACTOR: OBSERVATIONS: 
(a) LTC Long Term Care Facility Usage No definitive observations. (Very few Active TB cases 
in KS were in LTC settings.) 
(b) JAIL Incarceration History No definitive observations. (Very few Active TB cases 
in KS were had incarceration histories.) 
(c) HOMELESS Homelessness History Roughly 1 in 13 Active TB cases in KS were 
homeless. 
(d) HIV HIV Status Roughly 1 in 20 Active TB cases in KS were HIV 
positive. 
(e) IV DRUG IV Drug Usage Roughly 1 in 20 Active TB cases in KS abused IV 
drugs. 
(f) NON-IV DRUG Non-IV Drug Usage Roughly 1 in 13 Active TB cases in KS abused non-IV 
drugs. 
(g) ALCOHOL Alcohol Abuse Roughly 1 in 5 Active TB cases in KS abused alcohol. 
(h) CIGARETTES Smoking Status (Cigarettes) Roughly 1 in 3 Active TB cases in KS smoked 
cigarettes. 
(i) SENSITIVITY Sensitivity/Resistance (to at least 
one first-line TB drug) 
Roughly 1 in 7 Active TB cases in KS were resistant to 
at least 1 First-Line TB drug. 
(j) USAORFOR USA/Foreign-Born Status **Roughly 2 in 3 Active TB cases in KS were foreign-
born. 
(k) SENSITIVITYxUSAORFOR Sensitivity Projected Across 
USA/Foreign-Born Status and 
classified by Ethnicity 
**When plotting Sensitivity status across U.S./Foreign-
born status, roughly 4 in 5 (or 80%) of “Resistant” 
cases were foreign-born. 
**Additionally, when looking at Ethnicity classifications 
(by color), 23 in 26 (or 88.5%) of “Resistant” cases 
were non-white. 
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                           (a) LTC       (b) JAIL 
 
                     (c) HOMELESS      (d) HIV 
Figure 3.3 (a, b, c, d) Risk Factor Visualizations by (a) LTC, (b) Jail, (c) Homeless, and (d) HIV 
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                          (e) IV DRUG       (f) NON-IV DRUG 
 
                       (g) ALCOHOL      (h) CIGARETTES 
Figure 3.3 (e, f, g, h) Risk Factor Visualizations by (e) IV-Drug Use, (f) Non IV-Drug Use, (g) 
Alcohol Abuse, and (h) Cigarette Use 
25 
 
 
                          (i) SENSITIVITY         (j) USAORFOR 
 
Foreign-Born, Resistant Cases: 
14/21 (66%) are Asian, 4/21 (19%) are Hispanic, 2/21 (10%) are Black, and 1/21 (5%) are White 
                                               (k) SENSIVITIYxUSAORFOR 
Figure 3.3 (i, j, k) TB Risk Factor Visualizations by (i) Sensitivity, (j) U.S. or Foreign-Born 
Status, and (k) Sensitivity Plotted Against U.S. or Foreign-Born Status, Stratified by Ethnicity 
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CDC WONDER Active TB Case Data (1993-2015) 
 The CDC has an online ad-hoc query system called WONDER, that is utilized for 
disseminating public health data and information for analysis. For the purposes of this project, 
WONDER’s Online Tuberculosis Information System (OTIS) data was used to extract data on 
Kansas and USA active TB data from years 1993-2015. 
 Upon viewing the KS data in the TB Risk Factor Visualization section, we observed that 
there was a high incidence of foreign-born cases of active TB in Kansas. When a foreign-born 
immigrant, traveler, student, or refugee arrives in the U.S. from a TB high-burden country, it is 
observed from literature that they have a significantly higher rate of developing active TB than 
those who are born in the U.S. In addition, drug resistance was more commonly seen in foreign-
born individuals. 
 
Question Formulations: 
These observations led to the asking of the following question: (1) Is the relative 
proportion of foreign-born cases of active TB greater in Kansas than the true proportion or 
overall burden of foreign-born cases (proportion of foreign-born cases in the U.S.)? 
Thereby, exploring the need for a greater focus to be made on the foreign-born subpopulations of 
TB cases in Kansas. In addition, to address the issue of drug resistance among these foreign-born 
individuals, a second question based on risk factors was formulated: (2) Is country of birth (U.S. 
vs foreign-born status) independent of multi-drug resistance? Finally, because multi-drug 
resistance is often correlated to therapy noncompliance, (cases where treatment regimens are not 
adhered to), a final question was made: (3) Is TB therapy administration method (self-
administered vs. DOT vs. both) independent of completion of therapy in Kansas TB cases? 
 
 
Testing of Questions: 
 To test these questions, three separate hypothesis tests were conducted: Test 1 – A one-
sample Z-test to compare proportions // Tests 2 & 3 – Chi-square tests to test independence of 
categorical variables with associated odds ratio calculations. 
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Results, Conclusions, and Discussion: 
 From the result of the first test, it was found that the proportion foreign-born active TB 
cases in Kansas were higher than in the general U.S. population (p-value = 0.001962). 
Although the reasoning for this proportional imbalance (e.g. higher rate of immigrants or refugee 
placements in Kansas or bad case managements) cannot be determined from this information, the 
findings led me to believe that a potentially helpful customization of the SCHD TB protocol manual 
can address cultural sensitivity issues (from CDC’s Promoting Cultural Sensitivity series). 
 From the results of the second and third tests, it was found that multi-drug resistance was 
not independent of U.S. or foreign-born status (p-value = 0.002951) and therapy 
administration methods were not independent of completion of therapy in Kansas (p-value 
= 0.001591). The respective odds ratio calculations returned found that foreign-born TB cases in 
Kansas were 24 times more likely to be MDR-TB cases than U.S.-born TB cases in Kansas 
and that active TB cases in Kansas who had some sort of DOT were 2.2 times more likely to 
finish therapy within 1 year as those who only self-administered their TB therapy. 
After seeing these results, it occurred to me that increased health communication and 
adherence to treatment by foreign-born individuals can drastically reduce cases of TB spreading in 
Kansas and mitigate state spending on TB treatment costs. Therefore, I decided to implement a 
translation service method utilizing technology (Google Translate) into the manual to potentially 
increase health communication between the health care worker and the foreign-born TB patient. 
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Hypothesis Testing: 
Test 1 (One-Sample Z-test for Proportions): 
Question: Is the relative proportion of foreign-born cases of TB greater in Kansas than the true 
proportion or overall burden of foreign-born cases (proportion of foreign-born cases in the U.S.)? 
𝑯𝟎: 𝑃𝐾𝑆 ≤ 𝑃, (where 𝜇 represents the true proportion of active TB Cases that are foreign-born) 
𝑯𝒂: 𝑃𝐾𝑆 > 𝑃 
Significance Level: 𝛼 = 0.05 
Decision Rule: Reject 𝐻0 if Z > Critical Value (1.645). 
Test Statistic:  n = 1471 
    ?̂? = 
# 𝑜𝑓 𝐹𝑜𝑟𝑒𝑖𝑔𝑛−𝐵𝑜𝑟𝑛 𝐶𝑎𝑠𝑒𝑠 𝑜𝑓𝐴𝑐𝑡𝑖𝑣𝑒 𝑇𝐵 𝑖𝑛 𝐾𝑆 
𝑇𝑜𝑡𝑎𝑙 # 𝑜𝑓 𝐴𝑐𝑡𝑖𝑣𝑒 𝑇𝐵 𝐶𝑎𝑠𝑒𝑠 𝑖𝑛 𝐾𝑆
 = 
764
1471
 = 0.5194 
    𝑝0 = 
# 𝑜𝑓 𝐹𝑜𝑟𝑒𝑖𝑔𝑛−𝐵𝑜𝑟𝑛 𝐶𝑎𝑠𝑒𝑠 𝑜𝑓 𝐴𝑐𝑡𝑖𝑣𝑒 𝑇𝐵 𝑖𝑛 𝑡ℎ𝑒 𝑈.𝑆.
𝑇𝑜𝑡𝑎𝑙 # 𝑜𝑓 𝐴𝑐𝑡𝑖𝑣𝑒 𝑇𝐵 𝐶𝑎𝑠𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑈.𝑆.
 = 
169,127
351,029
 = 0.4818 
  𝑍 =
𝑝− 𝑝0
√
𝑝0(1−𝑝0)
𝑛
=  
0.5194− 0.4818
√
(0.4818)(1−0.4818)
1471
= 2.8861 > 1.645 (Critical Value) 
From Standard Normal Table:  P(Z≤2.8861) = 𝛷(2.9) = 0.9984 
p-value: 1 – 𝛷(2.9) = 1 – 0.9984 = 0.0016 
Decision: Reject 𝐻0 in favor of 𝐻𝑎. 
Conclusion: The proportion of active TB cases that are foreign-born is greater in Kansas than the 
proportion of active TB cases that are foreign-born in the U.S (0.4818). (p-value: 0.0016) 
 
TABLE 4. KS vs U.S. TB Cases (Broken down by U.S.-Born vs. Foreign-Born Status) (1993-2015) 
 Kansas USA 
U.S.-Born 689 180,591 
Foreign-Born 764 169,127 
Not Reported 18 1,311 
TOTAL 1471 351,029 
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Test 2 (Chi-Square Test of Independence and Odds Ratio Calculation): 
Question: Is U.S./foreign-born status independent of multi-drug resistance? 
𝑯𝟎: U.S./Foreign-Born Status is independent of Multi-Drug Resistance Status 
𝑯𝒂: U.S./Foreign-Born Status is not independent of Multi-Drug Resistance Status 
Significance Level: 𝛼 = 0.05 
Decision Rule: Reject 𝐻0 if 𝜒
2 > Critical Value 
Test Statistic:  df = (r-1)(c-1) = (2-1)(2-1) = 1 
    From 𝜒2 Distribution Table: 𝜒2(𝑑𝑓=1,𝛼=0.05)  = 3.84 (Critical Value) 
  𝜒2 =  ∑
(|𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑−𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑|−0.5)2
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑
  (With Yates’ Continuity Correction) 
        = 
(|13.5−7.4866|−0.5)2
7.5
+ 
(|586.5−592.5134|−0.5)2
592.5
+ 
(|0.5−6.5134|−0.5)2
6.5
+ 
(|521.5−515.4866|−0.5)2
515.5
  
        = 8.84 > 3.84 (Critical Value) 
Decision: Reject 𝐻0 in favor of 𝐻𝑎. 
Conclusion: U.S./foreign-born status is not independent of MDR status (P-Value: 0.002951). 
 
ODDS RATIO CALCULATION (Test 2): 
Odds of Risk Factor (MDR-TB) in Foreign Born: 13.5/586.5 = 0.2302 
Odds of Risk Factor (Foreign-Born) in Controls (Not MDR-TB): 0.5/521.5 = 0.0009588 
Odds Ratio: (13.5/586.5) / (0.5/521.5) = 24.0077 
Conclusion: The foreign-born TB cases in Kansas were 24 times more likely to be MDR-TB cases 
than U.S.-born TB cases in Kansas. 
TABLE 5. U.S./FOREIGN-BORN STATUS vs. MDR-TB STATUS (Kansas 1993-2015) 
[Haldane’s Correction (+0.5) // Expected Values in Parenthesis for 𝝌𝟐 Calculations] 
 Yes No TOTAL: 
Foreign-Born 13.5 (7.4866) 586.5 (592.5134) 600 
U.S.-Born 0.5 (6.5134) 521.5 (515.4866) 522 
TOTAL: 14 1108 1122 
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Test 3 (Chi-Square Test of Independence and Odds Ratio Calculation): 
Question: Is TB therapy administration method (self-administered vs. DOT vs. both) independent 
of completion of therapy in cases of active TB in Kansas? 
𝑯𝟎: Treatment Administration Method is independent of Therapy Completion Status. 
𝑯𝒂: Treatment Administration Method is not independent of Therapy Completion Status. 
Significance Level: 𝛼 = 0.05 
Decision Rule: Reject 𝐻0 if 𝜒
2 > Critical Value 
Test Statistic: df = (r-1)(c-1) = (3-1)(2-1) = 2 
    From 𝜒2 Distribution Table: 𝜒2(𝑑𝑓=2,𝛼=0.05)  = 5.9915 (Critical Value) 
  𝜒2 =  ∑
(𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑−𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑)2
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑
 = 
(812−799.45)2
799.45
+
(71−77.48)2
77.48
+
(86−92.07)2
92.07
+
(65−77.55)2
77.55
+
(14−7.52)2
7.52
+
(15−8.93)2
8.93
  
        = 12.887 > 5.9915 (Critical Value) 
Decision: Reject 𝐻0 in favor of 𝐻𝑎. 
Conclusion: Treatment method is not independent of therapy completion (P-Value: 0.001591). 
 
ODDS RATIO CALCULATION (Test 3): 
Odds of Therapy Completion in Cases with some sort of DOT: 898/80 = 11.2250 
Odds of Therapy Completion in Cases without any sort of DOT: 71/14 = 5.0714 
Odds Ratio: (898/80) / (71/14) = 2.2134 
Conclusion: The active TB cases in Kansas who had some sort of DOT were 2.2 times more likely 
to finish therapy within 1 year as those who only self-administered their TB therapy. 
 
TABLE 6. Treatment Method vs. Completion of Therapy (Kansas 1993-2015) 
(Rearranged as 2x2 Table for Odds Ratio) 
 Yes No TOTAL: 
Some Sort of DOT 898 80 978 
Self Only (No DOT) 71 14 85 
TOTAL: 969 94 1063 
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Additional Data Collection via SurveyMonkey 
E-DOT implementation was thought to be a potentially helpful way to mitigate costs of TB 
treatment and the translation service methods utilizing technology (Google Translate) was an idea 
for potentially lessening the burden of foreign-born cases of active TB in Kansas by increasing TB 
treatment adherence and health communication. 
A survey of health care workers at the SCHD was conducted via SurveyMonkey over 2 
weeks to assess general knowledge of video-communication and translation services and to gain 
their feedback about e-DOT and Google Translate. Of about 30 staff, there were 19 responses. 
Health Communication Survey Results: 
Regarding e-DOT: 
 7/19, or roughly 37% of respondents had never used video-communication before. 
o After respondents were introduced to DOT and its associated time/monetary costs, 
they were introduced to the e-DOT method. 17/19, or roughly 89.5% of 
respondents thought that e-DOT would be a good way of providing remote therapy. 
 Very valid concerns of the two respondents that didn’t think it was a good 
idea were: 1) manipulation of e-DOT observation and 2) lost client-
caregiver connection and other observations without direct contact. 
 
Figure 3.4(a) eDOT Survey Results 
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Regarding Google Translate Usage: 
 17/19, or roughly 89.5% of respondents claimed to be “very familiar” or “decently familiar” 
with using a smartphone or tablet to seek answers to questions and 11/19, or roughly 58% 
of respondents stated that they were familiar with Google Translate. 
o After being presented a scenario where patient translation was critical and given 
directions for utilizing Google Translate to help with translation, 16/19, or roughly 
84% of respondents found the instructions easy and useful to follow/implement. 
 The concerns of the 3 respondents who replied “no” were the same: “could 
not get the “speaker” to work”. This is because Google translate currently 
only offers 32 of 100+ languages in “conversation mode”. 
 To address this confusion, instructions in the manual were clarified: 
“if available, press the speaker icon ( )…” 
 
Figure 3.4(b) Google Translate Survey Results 
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3.2.4) Producing the Product: 
After the culmination of qualitative and quantitative research along with the addressing of 
the research question for customizing the manual to fit the needs of SCHD and Kansas, the TB 
manual writing commenced. From observing the necessities of the manual, I decided to organize 
the manual into 6 parts:  
MANUAL PARTS: 
1) Introduction 
2) LTBI Management 
3) Active TB Management 
4) Adherence Promoting Strategies 
5) Contact Investigations & Infection Control 
6) References & Appendices 
 
 
Additionally, there were 5 customizations outlined in the previous research sections that 
were included in the manual: 
CUSTOMIZATIONS: 
1) Use of graphics and visually pleasing tables to accompany procedures (e.g. Tuberculin Skin 
Test section and TB) 
2) Electronic DOT (e-DOT) Implementation 
3) Promoting Cultural Sensitivity 
4) Translator Services & Google Translate Implementation 
5) Other Relevant SCHD/KS Customizations (e.g. KS State Statutes, KS TB Infection Control 
Measures, SCHD TB forms). 
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SCHD TB Protocol Manual Navigation (6 Parts, 14 Sections): 
Part 1: An Introduction to Tuberculosis Control 
 I. Introduction 
 II. Effective TB Control Programs 
 III. Pathogenesis of Tuberculosis 
Part 2: Latent Tuberculosis Infection Management 
 IV. Targeted Tuberculin Testing & IGRA 
o CUSTOM: Graphics accompanying procedures (e.g. Tuberculin Skin Test section) 
 
Figure 3.5 (a) Graphics to Accompany TST Procedures 
 V. Treatment of Latent TB Infection 
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Part 3: Active Tuberculosis Disease Management 
 VI. Diagnosis of Tuberculosis 
 VII. Treatment of Tuberculosis 
o CUSTOM: Colorful TB Treatment Regimen Tables 
 
Figure 3.5 (b) Colorful TB Treatment Regimen Tables 
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Part 4: Adherence Promoting Strategies 
 VIII. Promoting Treatment Adherence 
o CUSTOM: Electronic DOT (e-DOT) Implementation Instructions 
 
Figure 3.5 (c) E-DOT Implementation Instructions (CDC) 
 IX. Managing Non-Adherence 
o CUSTOM: Kansas State Statutes 
 
Figure 3.5 (d) Inclusion of Kansas State Statutes 
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 X. Promoting Cultural Sensitivity 
o CUSTOM: Promoting Cultural Sensitivity (CDC series adaptation) 
 
Figure 3.5 (e) Promoting Cultural Sensitivity Booklets (CDC) 
 
o CUSTOM: Translator Services & Google Translate Implementation Instructions 
 
Figure 3.5 (f) Google Translate 
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Part 5: Contact Investigations & Infection Control 
 XI. Contact Investigations 
 XII. Infection Control 
o CUSTOM: Kansas TB Infection Control Measures 
 
Figure 3.5 (g) Customized Infection Control Plans as recommended by the KDADS 
Part 6: References & Appendices 
 XIII. References 
 XIV. Appendices 
o CUSTOM: SCHD TB Forms (SCHD Treatment Agreement Forms, SCHD 
Medication Administration Record (MAR) Form, SCHD Contact Investigation Form, 
& KDHE Interpreter/Translator Vendor List) 
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Figure 3.5 (h) Appendices Including Forms Used by the SCHD 
 
 
3.2.5) External Review: 
Upon completion of the TB protocol manual, review of the manual’s content by external 
sources was necessary for validation. The manual contents, especially the tables with critical 
information involving medical dosing for TB treatments, were reviewed in detail and compared 
alongside CDC recommendations with both SCHD’s Communicable Disease / TB Program 
Manager (Maria Shoultys, RN) and a Stanford University School of Medicine resident physician 
(Joseph Tseng, MD - Department of Radiology). Adjustments found from the reviews were made 
accordingly. 
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Part 3: Results / Discussion 
3.3.1) Document Produced 
 The final document produced for this capstone project is the Saline County Health 
Department Guidelines for the Prevention, Diagnosis, and Treatment of Tuberculosis (2017) 
(written and adapted for use by the Saline County Health Department and other local health 
departments in Kansas). 
 After the inclusion of page breaks, the TB protocol manual is 89 pages long (83 pages 
when not including the cover page, preface, and table of contents). 
 
3.3.2) Potential Areas of Improvement 
 The 2 areas of potential improvement for this TB protocol manual are 1) even more picture 
graphics to aid in procedural instructions (e.g. Contact Investigation and Infection Control 
sections), and 2) more information on Second-Line TB drugs and the ways to implement anti-TB 
drugs in the case of MDR or XDR-TB. 
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